Endpoints News 9. März 2026 AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in China
Endpoints News 9. März 2026 Xenon gets Phase 3 win with epilepsy drug, setting up FDA approval filing
Endpoints News 9. März 2026 GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
Endpoints News 7. März 2026 UniQure’s dispute with FDA; Zealand’s obesity readout; China takes on world’s most expensive medicines; and more
Endpoints News 6. März 2026 Pfizer gets obesity drug approval in China shortly after buying local rights